GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc.
(Nasdaq: NVAX), a biotechnology company dedicated to developing and
commercializing next-generation vaccines for serious infectious
diseases, today announced the appointment of Richard Rodgers, MBA to its board as an
independent director. Mr. Rodgers brings extensive experience in
biopharmaceutical management to his role on the Novavax Board of
Directors.
"Rick's deep experience in the pharmaceutical industry coupled
with his extensive acumen in building rapidly growing companies and
financial leadership will be invaluable as we continue the
commercialization of our COVID-19 vaccine and expand our vaccine
pipeline," said Stanley C. Erck,
President and Chief Executive Officer, Novavax.
From 2010 to 2013, Mr. Rodgers was co-founder, Executive Vice
President, Chief Financial Officer, Secretary, and Treasurer of
TESARO, Inc., a biopharmaceutical company that was acquired in
January 2019 by GSK for over
$5 billion. From 2009 to 2010, Mr.
Rodgers served as the Chief Financial Officer and Senior Vice
President of Abraxis BioScience, Inc., a biotechnology company that
was acquired by Celgene for $2.9
billion. From 2004 to 2008, Mr. Rodgers served as Senior
Vice President, Controller and Chief Accounting Officer of MGI
PHARMA, Inc., a biopharmaceutical company that was acquired in
January 2008 by Eisai for
$3.9 billion.
Mr. Rodgers currently serves on the boards of directors and as
the chair of the audit committee and member of the compensation
committee of Ocuphire Pharma, Inc., Sagimet Biosciences, Inc., and
Ardelyx, Inc.
"This is a very exciting time to be joining the Novavax Board,"
said Mr. Rodgers. "I look forward to working with my fellow
directors to support Novavax as it commercializes its first
globally-approved vaccine and continues its growth into new vaccine
areas."
Mr. Rodgers holds a Bachelor of Science degree in Financial
Accounting from St. Cloud State
University and a Master of Business Administration in
Finance from the University of
Minnesota, Carlson School of
Business.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases. The
company's proprietary recombinant technology platform harnesses the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. The Novavax COVID-19 vaccine, has received
authorization from multiple regulatory authorities globally,
including the U.S. Food and Drug Administration, the European
Commission, and the World Health Organization. The vaccine is
currently under review by multiple regulatory agencies worldwide,
including for additional populations and indications such as
adolescents and as a booster. In addition to its COVID-19 vaccine,
Novavax is also currently evaluating its COVID-19-Influenza
Combination vaccine candidate in a Phase 1/2 clinical trial, its
quadrivalent influenza investigational vaccine candidate, and an
Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent
format Omicron-based / original strain-based vaccine. These vaccine
candidates incorporate Novavax' proprietary saponin-based Matrix-M
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on LinkedIn.
Forward-Looking Statements
Statements herein relating
to the future of Novavax, its operating plans and prospects, the
timing of clinical trial results, the ongoing development of
NVX-CoV2373, NVX-CoV2515, a bivalent vaccine candidate, a
quadrivalent influenza investigational vaccine candidate, and a
COVID-19-Influenza Combination investigational vaccine candidate,
the scope, timing and outcome of future regulatory filings and
actions, additional worldwide authorizations of NVX-CoV2373 for use
in adults and adolescents, and as a booster, the evolving COVID-19
pandemic, the potential impact and reach of Novavax and NVX-CoV2373
in addressing vaccine access, controlling the pandemic and
protecting populations, the efficacy, safety, intended utilization,
and expected administration of NVX-CoV2373 and Novavax' other
vaccine candidates are forward-looking statements. Novavax cautions
that these forward-looking statements are subject to numerous risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation,
challenges satisfying, alone or together with partners, various
safety, efficacy, and product characterization requirements,
including those related to process qualification and assay
validation, necessary to satisfy applicable regulatory authorities;
unanticipated challenges or delays in conducting clinical trials;
difficulty obtaining scarce raw materials and supplies; resource
constraints, including human capital and manufacturing capacity, on
the ability of Novavax to pursue planned regulatory pathways;
challenges meeting contractual requirements under agreements with
multiple commercial, governmental, and other entities; and those
other risk factors identified in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Novavax' Annual Report on Form
10-K for the year ended December 31, 2021 and subsequent
Quarterly Reports on Form 10-Q, as filed with the Securities and
Exchange Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in
this press release. You are encouraged to read our filings with the
SEC, available at www.sec.gov and www.novavax.com,
for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com
Logo -
https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/novavax-appoints-rick-rodgers-to-board-of-directors-301665391.html